Your browser is no longer supported. Please, upgrade your browser.
Settings
VBIV [NASD]
VBI Vaccines Inc.
Index- P/E- EPS (ttm)-0.21 Insider Own3.28% Shs Outstand242.94M Perf Week-2.77%
Market Cap762.44M Forward P/E- EPS next Y-0.10 Insider Trans0.00% Shs Float178.59M Perf Month-21.29%
Income-46.20M PEG- EPS next Q-0.06 Inst Own53.30% Short Float21.57% Perf Quarter-14.72%
Sales1.10M P/S693.12 EPS this Y53.80% Inst Trans-3.10% Short Ratio6.03 Perf Half Y1.81%
Book/sh0.71 P/B3.96 EPS next Y64.30% ROA-27.30% Target Price- Perf Year80.13%
Cash/sh0.44 P/C6.40 EPS next 5Y- ROE-34.30% 52W Range1.02 - 6.93 Perf YTD2.18%
Dividend- P/FCF- EPS past 5Y28.90% ROI-23.20% 52W High-59.45% Beta1.97
Dividend %- Quick Ratio7.50 Sales past 5Y2.10% Gross Margin- 52W Low175.49% ATR0.20
Employees127 Current Ratio7.60 Sales Q/Q-66.70% Oper. Margin- RSI (14)43.48 Volatility7.45% 6.72%
OptionableYes Debt/Eq0.09 EPS Q/Q-4.00% Profit Margin- Rel Volume0.47 Prev Close2.61
ShortableYes LT Debt/Eq0.09 EarningsMar 02 BMO Payout- Avg Volume6.39M Price2.81
Recom1.20 SMA20-4.08% SMA50-14.57% SMA200-15.85% Volume2,974,976 Change7.66%
Feb-25-21Initiated Jefferies Buy $7
Aug-27-20Upgrade Raymond James Outperform → Strong Buy $8 → $9
Jan-16-19Initiated Oppenheimer Outperform $9
Nov-01-17Initiated Canaccord Genuity Buy $10
Oct-10-16Initiated Laidlaw Buy $6
Jul-26-16Initiated Ladenburg Thalmann Buy
May-07-15Initiated Noble Financial Buy $7
Apr-21-21 08:50AM  
08:00AM  
Apr-12-21 08:00AM  
Apr-08-21 09:21AM  
Mar-16-21 11:37AM  
Mar-15-21 08:00AM  
Mar-10-21 09:26AM  
08:19AM  
08:01AM  
07:00AM  
Mar-09-21 06:02PM  
09:35AM  
Mar-02-21 06:42PM  
09:25AM  
08:00AM  
Mar-01-21 08:00AM  
Feb-22-21 07:30AM  
Feb-02-21 08:00AM  
Jan-30-21 08:36AM  
Jan-22-21 02:13PM  
Jan-21-21 08:00AM  
Jan-15-21 08:00AM  
Dec-23-20 08:00AM  
Dec-14-20 08:41AM  
Dec-11-20 02:00PM  
Dec-07-20 08:00AM  
Dec-02-20 08:00AM  
Dec-01-20 08:00AM  
Nov-23-20 08:00AM  
Nov-19-20 10:45AM  
08:00AM  
Nov-18-20 08:00AM  
Nov-13-20 08:00AM  
Nov-12-20 08:47AM  
Nov-09-20 08:00AM  
Nov-05-20 04:15PM  
10:41AM  
Nov-04-20 12:31PM  
12:25PM  
Nov-02-20 08:00AM  
Oct-27-20 07:00AM  
Oct-26-20 08:00AM  
Oct-20-20 10:05AM  
Oct-18-20 09:04AM  
Oct-15-20 08:00AM  
Oct-09-20 05:45PM  
Oct-08-20 04:37PM  
08:00AM  
Sep-24-20 08:00AM  
Sep-19-20 07:00AM  
Sep-17-20 01:51PM  
08:00AM  
Sep-14-20 03:39PM  
08:00AM  
Sep-03-20 10:03AM  
Sep-01-20 12:30PM  
Aug-31-20 08:00AM  
Aug-30-20 09:10AM  
Aug-28-20 11:29AM  
09:20AM  
Aug-27-20 06:11PM  
04:39PM  
03:15PM  
02:16PM  
12:39PM  
Aug-26-20 08:00AM  
Aug-25-20 06:12AM  
Aug-20-20 08:00AM  
Aug-19-20 09:07AM  
Aug-12-20 03:31PM  
Aug-05-20 04:28PM  
09:00AM  
Aug-04-20 06:46AM  
Jul-31-20 09:25AM  
08:00AM  
Jul-29-20 06:48AM  
Jul-28-20 11:43AM  
11:37AM  
Jul-22-20 04:19PM  
Jul-15-20 04:28PM  
09:47AM  
Jul-07-20 06:52AM  
Jun-29-20 09:53AM  
Jun-26-20 10:29AM  
Jun-24-20 12:00PM  
11:30AM  
Jun-22-20 08:51AM  
08:45AM  
Jun-18-20 05:00PM  
Jun-17-20 08:00AM  
Jun-05-20 11:30AM  
Jun-04-20 07:06PM  
May-28-20 08:00AM  
May-27-20 08:00AM  
May-21-20 09:22AM  
May-20-20 08:35AM  
May-15-20 08:00AM  
May-11-20 08:16AM  
May-06-20 05:13PM  
09:15AM  
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. The company also develops coronavirus vaccine candidates, such as VBI-2902 and VBI-2901. In addition, it engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. The company primarily serves physicians and pharmacists through direct sales. It has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. The company also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. VBI Vaccines Inc. has collaboration with Coalition For Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PERCEPTIVE ADVISORS LLC10% OwnerApr 24Buy1.109,090,90910,000,00055,042,456Apr 28 09:00 AM